CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...
CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...
CSL has moved quickly to spend some of the money freed up by recent cuts, securing an option to buy the phase 3-ready blood clotting specialist VarmX in return for $117 million upfront. Last month, ...
CSL to downsize one-third of R&D division, AFR reports Company has not confirmed the number of job reductions Shares up 3% at over 6-week high July 15 (Reuters) - Australian biotech giant CSL Ltd (CSL ...
CSL recognized in Forbes and Statista's Best Large-sized Employer category for the fourth time since 2018. KING OF PRUSSIA, Pa., Feb. 21, 2023 /PRNewswire/ -- Global biotechnology leader CSL has again ...
Feb 14 (Reuters) - Australian biotech giant CSL Ltd said on Tuesday its first-half profit jumped 10%, beating analyst estimates, as a resurgence in blood plasma donations enabled it to boost sales and ...
CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF), an Australian biotech focused on developing vaccines and blood-derived therapies, on Tuesday announced plans to invest approximately $1.5B in the U.S. over the ...
Adds background and details on results in paragraphs 2-4 Aug 15 (Reuters) - Australia's CSL CSL.AX reported an annual profit on Tuesday that rose 8% as higher plasma collections helped the biotech ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results